Qu Hong
Qu Hong

Zeno Group forms a partnership with Qu Hong, who was most recently head of BCW in China. Qu Hong will serve as founder and CEO of Zeno China Consulting, which will operate independently of Zeno’s current China operations. Ruby Fu, who remains as president of Zeno’s existing China business, will be a senior advisor to Zeno China Consulting. Before joining BCW, Qu Hong was chief consultant at the Beijing offices of Edelman and Weber Shandwick, and led public policy consulting at Burson-Marsteller China. He has also worked with China’s Ministry of Commerce. “Partnering with Qu Hong on this joint venture re-imagines the traditional agency model in China. Zeno China Consulting is well-positioned to lead new conversations and outcomes,” said Zeno CEO Barby Siegel.


Hill+Knowlton Strategies launches its global Intelligence + Technology capability. Led by Grant Toups, Hill+Knowlton’s first global chief technology officer, the I+T group is comprised of 50+ technologists. The company has also partnered with Pendulum Intelligence, an AI and machine learning company, to codevelop products and services that address the evolving risk management needs of clients. The first of these is H+K Sonar, a tool built to address the commercial and reputation risk related to the rise of disinformation. The tool includes coverage of niche channels like Bitchute and Rumble, both of which have been recognized as breeding grounds of disinformation and malicious content. “We are developing an ecosystem of technology-based solutions drawing on data science, analytics and AI to drive our clients’ success and build resilience in the digital domain,” said H+K Strategies global chairman and CEO AnnaMaria DeSalva.


Accenture agrees to acquire Stagwell subsidiary ConcentricLife, a healthcare marketing agency with expertise in helping life sciences brands build an optimal brand experience. The deal is intended to reinforce Accenture Song’s continued investment in creating end-to-end solutions for its life sciences clients. ConcentricLife’s team has subject-matter expertise in rare diseases, healthcare and wellness. “This transaction will enhance our ability to help our clients achieve this vision in addressing the challenges of tomorrow,” said ConcentricLife CEO Ken Begasse Jr. “With this combined talent of diverse thinking and experiences, we will extend our ability to solve new patient and provider challenges in high-impact areas including access, clinical trials, and patient services.”